Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hole

Showing results (191-200 of 194) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 194 results.
Family Practice|December 2, 2008
Engaging patients, clinicians and health funders in weight management: the Counterweight Programme, Maria McQuigg, Jenny E Brown, et al.
Journal of Medicinal Chemistry|June 26, 2018
Scaffold-Hopping Approach To Discover Potent, Selective, and Efficacious Inhibitors of NF-κB Inducing KinaseNicole Blaquiere, Georgette M Castanedo, Jason D Burch, et al.
Journal of Medicinal Chemistry|January 5, 2024
PROTACs Targeting BRM (SMARCA2) Afford Selective <i>In Vivo</i> Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor ModelsMichael Berlin, Jennifer Cantley, Mark Bookbinder, et al.
Journal of Medicinal Chemistry|May 21, 2025
Correction to "PROTACs Targeting BRM (SMARCA2) Afford Selective <i>In Vivo</i> Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models"Michael Berlin, Jennifer Cantley, Mark Bookbinder, et al.
Pageof 20

Showing results (191-200 of 194) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 194 results.
Family Practice|December 2, 2008
Engaging patients, clinicians and health funders in weight management: the Counterweight Programme, Maria McQuigg, Jenny E Brown, et al.
Journal of Medicinal Chemistry|June 26, 2018
Scaffold-Hopping Approach To Discover Potent, Selective, and Efficacious Inhibitors of NF-κB Inducing KinaseNicole Blaquiere, Georgette M Castanedo, Jason D Burch, et al.
Journal of Medicinal Chemistry|January 5, 2024
PROTACs Targeting BRM (SMARCA2) Afford Selective <i>In Vivo</i> Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor ModelsMichael Berlin, Jennifer Cantley, Mark Bookbinder, et al.
Journal of Medicinal Chemistry|May 21, 2025
Correction to "PROTACs Targeting BRM (SMARCA2) Afford Selective <i>In Vivo</i> Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models"Michael Berlin, Jennifer Cantley, Mark Bookbinder, et al.
Pageof 20